April 16, 2025 - 13:35

In a groundbreaking move, a biotech company has announced its intention to patent the genetic technology behind the revival of extinct species, specifically targeting the woolly mammoth. This ambitious project is part of a broader effort to harness advanced genetic engineering techniques to restore lost biodiversity. The company claims that by utilizing CRISPR gene-editing technology, it can not only bring back the woolly mammoth but also adapt it to modern ecosystems, potentially addressing climate change and environmental degradation.
Critics argue that patenting such genetic technologies raises ethical concerns about ownership and the implications of playing God with nature. The notion of owning a species, even in a resurrected form, has sparked a heated debate among scientists, ethicists, and conservationists. Proponents of the initiative believe that the revival of the woolly mammoth could help restore tundra ecosystems and combat the impacts of global warming.
As the company moves forward with its ambitious plans, the conversation surrounding the intersection of technology, ethics, and conservation continues to evolve, highlighting the complexities of modern biotechnology.
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...